These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. Plotkin SA; Starr SE; Friedman HM; Gönczöl E; Weibel RE J Infect Dis; 1989 May; 159(5):860-5. PubMed ID: 2540247 [TBL] [Abstract][Full Text] [Related]
9. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. Adler SP; Starr SE; Plotkin SA; Hempfling SH; Buis J; Manning ML; Best AM J Infect Dis; 1995 Jan; 171(1):26-32. PubMed ID: 7798679 [TBL] [Abstract][Full Text] [Related]
10. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection. Liu Y; Freed DC; Li L; Tang A; Li F; Murray EM; Adler SP; McVoy MA; Rupp RE; Barrett D; Ye X; Zhang N; Beck K; Culp T; Das R; Song L; Vora K; Zhu H; Wang D; Espeseth AS; An Z; Musey L; Fu TM J Virol; 2019 Dec; 93(23):. PubMed ID: 31511385 [TBL] [Abstract][Full Text] [Related]
11. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376 [TBL] [Abstract][Full Text] [Related]
12. [The prevention of cytomegalovirus infection and disease by administration of biological products]. Ihara T Nihon Rinsho; 1998 Jan; 56(1):145-50. PubMed ID: 9465680 [TBL] [Abstract][Full Text] [Related]
13. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983 [TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus vaccines: current status. Starr SE Infect Agents Dis; 1992 Jun; 1(3):146-8. PubMed ID: 1365538 [TBL] [Abstract][Full Text] [Related]
15. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. Wang Z; La Rosa C; Maas R; Ly H; Brewer J; Mekhoubad S; Daftarian P; Longmate J; Britt WJ; Diamond DJ J Virol; 2004 Apr; 78(8):3965-76. PubMed ID: 15047812 [TBL] [Abstract][Full Text] [Related]
17. Vaccination with a Live Attenuated Cytomegalovirus Devoid of a Protein Kinase R Inhibitory Gene Results in Reduced Maternal Viremia and Improved Pregnancy Outcome in a Guinea Pig Congenital Infection Model. Schleiss MR; Bierle CJ; Swanson EC; McVoy MA; Wang JB; Al-Mahdi Z; Geballe AP J Virol; 2015 Oct; 89(19):9727-38. PubMed ID: 26178990 [TBL] [Abstract][Full Text] [Related]
18. A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men. Adler SP; Manganello AM; Lee R; McVoy MA; Nixon DE; Plotkin S; Mocarski E; Cox JH; Fast PE; Nesterenko PA; Murray SE; Hill AB; Kemble G J Infect Dis; 2016 Nov; 214(9):1341-1348. PubMed ID: 27521362 [TBL] [Abstract][Full Text] [Related]
19. Current prospects for immunization against cytomegaloviral disease. Adler SP Infect Agents Dis; 1996 Jan; 5(1):29-35. PubMed ID: 8789597 [TBL] [Abstract][Full Text] [Related]
20. Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine. Gerna G; Lilleri D New Microbiol; 2019 Jan; 42(1):1-20. PubMed ID: 30671581 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]